Rejuvenation Technologies

Rejuvenation Technologies is an early-stage biotech developing a novel therapeutic approach to target biological aging at its chromosomal source. Its core technology utilizes transient telomerase activation via modified mRNA delivered by proprietary lipid nanoparticles, aiming to safely reverse telomere shortening in specific tissues. The company is preparing to initiate its first clinical trials in Australia for pulmonary fibrosis, chronic liver disease, and a hematologic indication, leveraging accelerated regulatory pathways. With a seasoned leadership team and over $8M in grant funding secured since its founding, Rejuvenation is positioning itself at the forefront of the longevity and regenerative medicine space.

Proprietary platform using modified mRNA for transient telomerase (TERT) activation, delivered via targeted lipid nanoparticles (LNPs) to safely extend telomeres in specific human cells.

Rejuvenation competes in the emerging longevity biotech sector, facing companies like Telocyte (telomerase gene therapy) and Life Biosciences (cellular reprogramming), as well as larger biopharma exploring geroscience targets. Its differentiation lies in its transient mRNA-based telomerase activation approach, which aims for a superior safety profile compared to permanent genetic modifications.